(OMDA) Omada Health, Common Stock - Overview
Sector: Healthcare | Industry: Health Information Services | Exchange: NASDAQ (USA) | Market Cap: 1.068m USD | Total Return: -21.9% in 12m
Avg Turnover: 18.8M
Qual. Beats: 0
Rev. Trend: 99.7%
Warnings
Interest Coverage Ratio -4.7 is critical
Altman Z'' -7.84 < 1.0 - financial distress zone
Fakeout
Tailwinds
Idiosyncratic Leader, Confidence
Omada Health, Inc., based in South San Francisco, operates as a virtual care provider specializing in chronic condition management. Its core service suite includes cardiometabolic programs for diabetes and hypertension, physical therapy for musculoskeletal issues, and behavioral health support. The company also provides integrated clinical support for patients utilizing GLP-1 medications for weight management.
The business utilizes a B2B2C model, distributing its digital health interventions through self-insured employers, health plans, and pharmacy benefit managers. Within the Health Care Technology sector, firms often focus on virtual-first care to reduce long-term medical claims costs by improving patient adherence through remote monitoring and data-driven coaching.
Investors can further examine the companys valuation metrics and growth trajectory on ValueRay. Omada Health was incorporated in 2011 and leverages a direct sales force alongside strategic channel partnerships to scale its virtual care delivery across the United States.
- Enterprise contract renewals and health plan partnerships drive long-term recurring revenue
- GLP-1 weight management program adoption accelerates membership growth and service fees
- Musculoskeletal and physical therapy expansion diversifies revenue beyond cardiometabolic care
- High customer acquisition costs and sales force overhead pressure operating margins
- Regulatory shifts in telehealth reimbursement impact virtual care delivery profitability
| Net Income: -6.30m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 31.15 > 1.0 |
| NWC/Revenue: 70.86% < 20% (prev 28.12%; Δ 42.75% < -1%) |
| CFO/TA 0.07 > 3% & CFO 22.5m > Net Income -6.30m |
| Net Debt/EBITDA: error (cannot be calculated) |
| Current Ratio: 3.92 > 1.5 & < 3 |
| Outstanding Shares: last quarter (58.9m) vs 12m ago 5.70% < -2% |
| Gross Margin: 66.22% > 18% (prev 0.62%; Δ 6.56k% > 0.5%) |
| Asset Turnover: 127.6% > 50% (prev 134.3%; Δ -6.73% > 0%) |
| Interest Coverage Ratio: -4.74 > 6 (EBITDA TTM -1.34m / Interest Expense TTM 1.48m) |
| A: 0.66 (Total Current Assets 269.4m - Total Current Liabilities 68.7m) / Total Assets 302.8m |
| B: -1.52 (Retained Earnings -459.7m / Total Assets 302.8m) |
| C: -0.03 (EBIT TTM -7.00m / Avg Total Assets 222.0m) |
| D: -6.69 (Book Value of Equity -459.7m / Total Liabilities 68.7m) |
| Altman-Z'' = -7.84 = D |
| DSRI: 0.91 (Receivables 40.0m/29.3m, Revenue 283.3m/189.7m) |
| GMI: 0.93 (GM 66.22% / 61.66%) |
| AQI: 0.36 (AQ_t 0.08 / AQ_t-1 0.23) |
| SGI: 1.49 (Revenue 283.3m / 189.7m) |
| TATA: -0.10 (NI -6.30m - CFO 22.5m) / TA 302.8m) |
| Beneish M = -3.28 (Cap -4..+1) = AA |
As of June 01, 2026, the stock is trading at USD 17.97 with a total of 1,441,119 shares traded.
Over the past week, the price has changed by +9.31%,
over one month by +23.25%,
over three months by +39.30% and
over the past year by -21.87%.
Omada Health, Common Stock has no consensus analysts rating.
| Analysts Target Price | 22.9 | 27.5% |
P/E Forward = 588.2353
P/S = 3.7709
P/B = 4.5605
Revenue TTM = 283.3m USD
EBIT TTM = -7.00m USD
EBITDA TTM = -1.34m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 856.5m USD (1.07b + (null Debt) - CCE 211.8m)
Interest Coverage Ratio = -4.74 (Ebit TTM -7.00m / Interest Expense TTM 1.48m)
EV/FCF = 39.93x (Enterprise Value 856.5m / FCF TTM 21.5m)
FCF Yield = 2.50% (FCF TTM 21.5m / Enterprise Value 856.5m)
FCF Margin = 7.57% (FCF TTM 21.5m / Revenue TTM 283.3m)
Net Margin = -2.22% (Net Income TTM -6.30m / Revenue TTM 283.3m)
Gross Margin = 66.22% ((Revenue TTM 283.3m - Cost of Revenue TTM 95.7m) / Revenue TTM)
Gross Margin QoQ = 62.39% (prev 70.75%)
Tobins Q-Ratio = 2.83 (Enterprise Value 856.5m / Total Assets 302.8m)
Interest Expense / Debt = unknown (Interest Expense 1.48m / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = -5.53m (EBIT -7.00m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.92 (Total Current Assets 269.4m / Total Current Liabilities 68.7m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA -1.34m)
Debt / FCF = unknown (Net Debt none / FCF TTM 21.5m)
Total Stockholder Equity = 223.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -2.84% (Net Income -6.30m / Total Assets 302.8m)
RoE = -0.92% (Net Income TTM -6.30m / Total Stockholder Equity 683.6m)
RoCE = -2.99% (EBIT -7.00m / Capital Employed (Total Assets 302.8m - Current Liab 68.7m))
RoIC = -3.20% (negative operating profit) (NOPAT -5.53m / Invested Capital 172.9m)
WACC = 10.35% (E(1.07b)/V(1.07b) * Re(10.35%) + (debt-free company))
Discount Rate = 10.35% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 81.65 | Cagr: 2.50%
[DCF] Terminal Value 68.76% ; FCFF base≈21.5m ; Y1≈21.5m ; Y5≈22.8m
[DCF] Fair Price = 4.45 (EV 264.8m - Net Debt 0.0 = Equity 264.8m / Shares 59.4m; r=10.35% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.75 | # QB: 0
Revenue Correlation: 99.69 | Revenue CAGR: 45.58% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.07 | Chg30d=+65.81% | Revisions=+25% | Analysts=5
EPS next Quarter (2026-09-30): EPS=0.09 | Chg30d=+24.72% | Revisions=+43% | Analysts=5
EPS current Year (2026-12-31): EPS=0.33 | Chg30d=+71.53% | Revisions=+60% | GrowthEPS=+110.9% | GrowthRev=+25.8%
EPS next Year (2027-12-31): EPS=0.48 | Chg30d=+32.88% | Revisions=+40% | GrowthEPS=+45.9% | GrowthRev=+19.9%
[Analyst] Revisions Ratio: +60%